Bioceres Crop Solutions Stock Earnings Reports

Bioceres reported fiscal Q1 results showing lower revenues ($77.5M, down 17% YoY) driven by a deliberate shift in the seed business to a more capital-efficient model and timing effects in Latin America. Despite the revenue decline, gross profit was nearly flat at $36.2M and gross margin expanded ~650 bps to 47% due to improved product mix and phasing out low-margin sales. Adjusted EBITDA rose materially (+61% YoY to $13.6M) supported by roughly $5.9M in operating cost reductions and better margins. Working capital improved sequentially despite seasonality and the company is nearing its target of ~4 months of working capital relative to annual sales. Total financial debt decreased slightly to $242.5M, cash was $16.6M, and net financial debt was ~$225.9M with net debt / adjusted EBITDA improving to 6.8x. Management disclosed an active dispute with holders of secured convertible and nonconvertible notes and has reclassified certain debt as current (including estimated prepayment costs), while stating they will vigorously defend against the noteholders’ allegations. Operational priorities emphasized: improve revenue quality, protect margins, reduce SG&A (already achieved ~50% of targeted annualized savings in one quarter), and pursue profitability and capital efficiency.